Low-Dose Versus Standard-Dose Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multicenter Randomized Phase III Trial The Systemic Therapy in Advancing or Metastatic ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data from a phase 3 trial of the multi-center, randomized ...
Advanced digital pathology and biopsy analysis are used to identify patients who benefit from intensified prostate cancer treatment. The STAMPEDE trial demonstrated that adding Zytiga to standard ...
At the virtual European Society for Medical Oncology meeting, researchers presented a combined analysis from the STAMPEDE platform assessing androgen deprivation therapy (ADT) alone for high-risk ...
Abiraterone (Zytiga) added to standard of care treatments significantly improved survival outcomes in patients with high-risk prostate cancer or de novo metastatic castration-sensitive disease, ...
An artificial intelligence (AI) project has demonstrated progress towards developing personalised prostate cancer treatments, researchers reported. A team from University College London (UCL) used an ...
Dr. Nicholas James discusses why it is important to identify which patients with high-risk prostate cancer will truly benefit from intensified treatment. It is important to target intensified therapy ...
Among patients with metastatic or very high-risk nonmetastatic prostate cancer, lower prostate-specific antigen (PSA) levels during hormone-based therapy — particularly ≤ 0.2 ng/mL — were strongly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results